ArticleContemporary clinical trials2022

Onsite buprenorphine inductions at harm reduction agencies to increase treatment engagement and reduce HIV risk: Design and rationale.

Andres Perez-Correa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.